Fundraising Fox
Biovie
NASDAQ: BIVIBeverly, US · Founded 2013 · Nevada corporation
Find your way into Biovie
Sign up to see every warm intro you have to Biovie
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Biovie team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BioVie is a clinical-stage biopharmaceutical company developing bezisterim, a molecule studied for neurodegenerative and inflammatory conditions including Alzheimer's disease, Parkinson's disease, and Long COVID, alongside work on liver disease complications such as ascites. It also researches longevity and epigenetic mechanisms like DNA methylation.
Founders & leadership
JA
Jonathan AdamsCEO & CFO
PM
Penelope MarkhamChief Scientist
AS
Amrit ShahzadPresident & Secretary
JW
Joanne Wendy KimChief Financial Officer
JM
Joseph M. PalumboChief Medical Officer
Board
CD
Cuong DoBoard director
Reported raises · per SEC filings
Form D private placements$9.4M disclosed across 4 of 5 rounds · 2016–2022
▶$6MraisedJul 2022 · 1 investors · BiotechnologyRule 506(b)
▶$6MraisedJul 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sigmund RogichDirector
- Richard J. BermanDirector
- Robert Hariri, M.D., Ph.D.Director
- Joanne Wendy KimExecutive Officer
- Terren S. PeizerDirector
- Michael ShermanDirector
- Steve GorlinDirector
- Cuong DoExecutive Officer, Director
- Jim LangDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Jul 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.2MraisedJul 2018 · 5 investors · BiotechnologyRule 506(b)
▶$3.2MraisedJul 2018 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terren PeizerExecutive Officer, Director
- Julie AndersonExecutive Officer, Director
- Hari KumarDirector
- Mina SoochDirector
- Michael ShermanDirector
- Jim LangDirector
- Cuong DoDirector
- Jonathan AdamsExecutive Officer, Director
- Offering amount
- $6.2M
- Amount sold
- $3.2M
- First sale
- Jul 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$600KofferedMay 2017 · BiotechnologyRule 506(b)
▶$600KofferedMay 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James LangDirector
- Cuong DoDirector
- Julie AndersonDirector
- Jonathan AdamsExecutive Officer
- Amrit ShahzadExecutive Officer
- Penelope MarkhamExecutive Officer
- Offering amount
- $600K
- Minimum investment
- $10K
- Incorporated
- Corporation, Nevada, 2013
- Federal exemptions
- 06b
▶$200KraisedJan 2017 · 1 investors · BiotechnologyRule 506(b)
▶$200KraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James LangDirector
- Amrit ShahzadExecutive Officer
- Cuong DoDirector
- Jonathan AdamsExecutive Officer
- Penelope MarkhamExecutive Officer
- Amount sold
- $200K
- Minimum investment
- $200K
- Proceeds to insiders
- $10K
- First sale
- Jan 2017
- Incorporated
- Corporation, Nevada, 2013
- Federal exemptions
- 06b
▶$10KraisedOct 2016 · 1 investors · BiotechnologyRule 506(b)
▶$10KraisedOct 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan AdamsExecutive Officer
- Penelope MarkhamExecutive Officer
- Cuong DoDirector
- Amrit ShahzadExecutive Officer
- Offering amount
- $500K
- Amount sold
- $10K
- Minimum investment
- $10K
- Proceeds to insiders
- $10K
- First sale
- Oct 2016
- Incorporated
- Corporation, Nevada, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Biovie do?
- BioVie is a clinical-stage biopharmaceutical company developing bezisterim, a molecule studied for neurodegenerative and inflammatory conditions including Alzheimer's disease, Parkinson's disease, and Long COVID, alongside work on liver disease complications such as ascites. It also researches longevity and epigenetic mechanisms like DNA methylation.
- How much funding has Biovie raised?
- Biovie has disclosed $9.4M raised across 4 of its 5 known rounds.
- Where is Biovie headquartered?
- Biovie is headquartered in Beverly, US.